Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Retained Earnings (2016 - 2025)

Immucell (ICCC) has disclosed Retained Earnings for 16 consecutive years, with -$12.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings rose 15.83% year-over-year to -$12.4 million, compared with a TTM value of -$12.4 million through Sep 2025, up 15.83%, and an annual FY2024 reading of -$14.2 million, down 17.96% over the prior year.
  • Retained Earnings was -$12.4 million for Q3 2025 at Immucell, down from -$12.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$3.2 million in Q1 2022 and bottomed at -$14.7 million in Q3 2024.
  • Average Retained Earnings over 5 years is -$8.8 million, with a median of -$9.9 million recorded in 2023.
  • The sharpest move saw Retained Earnings rose 21.36% in 2022, then tumbled 165.01% in 2023.
  • Year by year, Retained Earnings stood at -$3.7 million in 2021, then tumbled by 66.7% to -$6.2 million in 2022, then tumbled by 92.65% to -$12.0 million in 2023, then dropped by 17.96% to -$14.2 million in 2024, then increased by 12.77% to -$12.4 million in 2025.
  • Business Quant data shows Retained Earnings for ICCC at -$12.4 million in Q3 2025, -$12.2 million in Q2 2025, and -$12.7 million in Q1 2025.